Hodgkin's lymphoma Posts on Medivizor
Navigation Menu

Hodgkin’s lymphoma Posts on Medivizor

How does brentuximab vedotin perform long-term for advanced Hodgkin lymphoma?

How does brentuximab vedotin perform long-term for advanced Hodgkin lymphoma?

Posted by on Jul 17, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study presents 5-year results for the targeted antibody therapy brentuximab vedotin (BV; Adcetris) for patients with advanced Hodgkin lymphoma (HL) who had not been previously treated. It found that BV with chemotherapy led to less recurrence of HL compared to chemotherapy alone. Some background The outcomes for patients with the...

Read More

Is changing treatment intensity after PET scan effective over the long-term for patients with advanced-stage Hodgkin lymphoma?

Is changing treatment intensity after PET scan effective over the long-term for patients with advanced-stage Hodgkin lymphoma?

Posted by on Jul 17, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study reported the long-term effectiveness and safety outcomes of changing treatment intensity after a PET scan for patients with advanced-stage Hodgkin lymphoma (HL). The data showed that reducing treatment intensity after a negative PET scan and continuing standard-dose treatment after a positive PET scan was safe and effective over...

Read More

Comparing pembrolizumab and brentuximab vedotin for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma.

Comparing pembrolizumab and brentuximab vedotin for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma.

Posted by on Jun 27, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell The authors compared the safety and effectiveness of pembrolizumab (Keytruda) and brentuximab vedotin (BV; Adcetris) for the treatment of patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). The study found that pembrolizumab had better survival without cancer worsening compared to BV in these...

Read More

Evaluating the use of high-dose chemotherapy for the treatment of patients with high-risk relapsed Hodgkin lymphoma.

Evaluating the use of high-dose chemotherapy for the treatment of patients with high-risk relapsed Hodgkin lymphoma.

Posted by on Jun 13, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to evaluate high-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) for the treatment of patients with high-risk relapse (HRR) classical Hodgkin’s lymphoma (cHL). The authors concluded that the outcomes of patients with HRR cHL have improved over the last 15 years with...

Read More

Does combining brentuximab vedotin with chemotherapy reduce the risk of consolidative radiotherapy for patients with early-stage unfavorable-risk Hodgkin lymphoma?

Does combining brentuximab vedotin with chemotherapy reduce the risk of consolidative radiotherapy for patients with early-stage unfavorable-risk Hodgkin lymphoma?

Posted by on Jun 6, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated whether brentuximab vedotin (Adcedris; BC) + AVD (doxorubicin, vinblastine, and dacarbazine) chemotherapy combination resulted in a reduction or elimination of consolidative radiotherapy in early-stage unfavorable-risk Hodgkin lymphoma (HL). The data showed that the BV+AVD combination with and without...

Read More

Long-term outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma.

Long-term outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma.

Posted by on May 30, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the long-term outcomes of radiation, chemotherapy, or both for the treatment of patients with nodular lymphocyte-predominant Hodgkin’s lymphoma (NLPHL). The data showed that the overall survival was excellent regardless of treatment type. Some background NLPHL is an uncommon type of Hodgkin lymphoma...

Read More

Evaluating the safety and effectiveness of brentuximab vedotin for children with high-risk Hodgkin lymphoma.

Evaluating the safety and effectiveness of brentuximab vedotin for children with high-risk Hodgkin lymphoma.

Posted by on May 23, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of incorporating brentuximab vedotin (BV; Adcetris) as a substitution for vincristine in the OEPA (vincristine, etoposide, prednisone, doxorubicin) or COPD (cyclophosphamide, vincristine, prednisone, dacarbazine) chemotherapy regimen in children with high-risk classical...

Read More

Is autologous stem cell transplantation after anti-PD-1 therapy an effective treatment for patients with relapsed or refractory Hodgkin lymphoma?

Is autologous stem cell transplantation after anti-PD-1 therapy an effective treatment for patients with relapsed or refractory Hodgkin lymphoma?

Posted by on May 15, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell The authors assessed the effectiveness of autologous stem cell transplantation (ASCT) after anti-PD-1 therapy for the treatment of patients with high-risk relapsed/refractory (r/r) Hodgkin lymphoma (HL). The study found that ASCT after anti-PD-1 therapy had very good outcomes in patients with r/r HL. Some background Standard...

Read More

How effective is involved field radiotherapy after autologous hematopoietic stem-cell transplantation in patients with high-risk relapsed/refractory lymphoma?

How effective is involved field radiotherapy after autologous hematopoietic stem-cell transplantation in patients with high-risk relapsed/refractory lymphoma?

Posted by on Apr 4, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell The authors assessed the safety and efficacy of involved-field radiotherapy (IFRT) after autologous hematopoietic stem-cell transplantation (ASCT) in patients with high-risk relapsed/refractory (r/r) lymphoma. The study found that IFRT given soon after ASCT provided durable responses and was well tolerated in these patients. Some...

Read More

Evaluating the effectiveness of BGD therapy in relapsed/refractory Hodgkin lymphoma

Evaluating the effectiveness of BGD therapy in relapsed/refractory Hodgkin lymphoma

Posted by on Mar 28, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of the BGD (bendamustine, gemcitabine, and dexamethasone) regimen in patients with previously treated Hodgkin lymphoma (HL). This study concluded that BGD is well-tolerated and highly effective in these patients.  Some background Hodgkin lymphoma (HL) is a cancer that...

Read More

Long-term outcomes of patients with relapsed or refractory nodular lymphocyte-predominant Hodgkin lymphoma

Long-term outcomes of patients with relapsed or refractory nodular lymphocyte-predominant Hodgkin lymphoma

Posted by on Mar 28, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to evaluate the long-term outcomes of patients with relapsed or refractory (r/r) nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). The data showed that first- and second-line therapies are effective over the long-term for these patients. Some background NLPHL is an uncommon type of Hodgkin lymphoma (HL). It...

Read More

Relapsed or refractory Hodgkin lymphoma: how does stopping and restarting nivolumab impact patient outcomes?

Relapsed or refractory Hodgkin lymphoma: how does stopping and restarting nivolumab impact patient outcomes?

Posted by on Mar 28, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to evaluate the safety and effectiveness of stopping and restarting nivolumab (Opdivo) in patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL).   The authors concluded that nivolumab retreatment is well tolerated and effective in patients who achieved complete response (CR; complete...

Read More